SEARCH

SEARCH BY CITATION

References

  • 1
    Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 29948.
  • 2
    Needleman P, Moncada S, Bunting S, Vane JR, Hamberg M, Samuelsson B. Identification of an enzyme in platelet microsomes which generates Thromboxane A2 from prostaglandin endoperoxides. Nature 1976; 261: 55860.
  • 3
    Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 6635.
  • 4
    Moncada S, Gryglewski R, Bunting S, Vane JR. Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potential inhibitor of platelet aggregation. Lancet 1977; 1: 1820.
  • 5
    Baenziger NL, Becherer PR, Majerus PW. Characterization of prostacyclin synthesis in cultured human arterial smooth muscle cells, venous endothelial cells and skin fibroblasts. Cell 1979; 16: 96774.
  • 6
    Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. Br Med J 2005; 330: 136673.
  • 7
    Fosbøl EL, Gislason GH, Jacobsen S, Folke F, Hansen ML, Schramm TK, Sørensen R, Rasmussen JN, Andersen SS, Abildstrom SZ, Traerup J, Poulsen HE, Rasmussen S, Køber L, Torp-Pedersen C. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 2009; 85: 1907.
  • 8
    Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 9549.
  • 9
    Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E. Cardiovascular risk of celecoxib in randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008; 117: 210413.
  • 10
    McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase. JAMA 2006; 296: 163344.
  • 11
    Grosser T, Fries S, FitzGerald GA. Biologic basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116: 416.
  • 12
    Patrignani P, Sciulli MG, Manarini S, Santini G, Cerletti C, Evangelista V. COX-2 is not involved in Thromboxane biosynthesis by activated human platelets. J Physiol Pharmacol 1999; 50: 6617.
  • 13
    Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2- dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 02: 8405.
  • 14
    Wong E, Huang J, Tagari P, Riendeau D. Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits. Atherosclerosis 2001; 157: 393402.
  • 15
    Créminon C, Habib A, Maclouf J, Pradelles P, Grassi J, Frobert Y. Differential measurement of constitutive (COX-1) and inducible (COX-2) cyclooxygenase expression in human umbilical vein endothelial cells using specific immunometic enzyme immunoassays. Biochim Biophys Acta 1995; 1254: 3418.
  • 16
    Rudic RD, Brinster D, Cheng Y, Fries S, Song WL, Austin S, Coffman TM, FitzGerald GA. COX-2-derived prostacyclin modulates vascular remodeling. Circ Res 2005; 96: 12407.
  • 17
    Topper JN, Cai J, Falb D, Gimbrone MA Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA 1996; 93: 1041722.
  • 18
    Atsuta H, Uchiyama T, Kanai H, Iso T, Tanaka T, Suga T, Maeno T, Arai M, Nagai R, Kurabayashi M. Effects of a stable prostacyclin analogue beraprost sodium on VEGF and PAI-1 gene expression in vascular smooth muscle cells. Int J Cardiol 2009; 132: 4118.
  • 19
    Kirchrath J, Debey S, Glandorff C, Kirchrath L, Schror K. Gene expression profile of the Gs-coupled prostacyclin receptor in human vascular smooth muscle cells. Biochem Pharmacol 2004; 67: 75665.
  • 20
    Cozzolino D, Coppola L, Masi S, Salvatore T, Sasso F, Lucia D, Gentile S, Torella R. Short- and long-term treatments with iloprost in diabetic patients with peripheral vascular disease: effects on the cardiovascular risk factor plasminogen activator inhibitor type-1. Eur J Clin Pharmacol 1999; 55: 4914979.
  • 21
    Eitzman D, Westrick R, Nabel E, Ginsburg D. Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice. Blood 2000; 95: 57780.
  • 22
    Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342: 1792801.
  • 23
    Hamsten A, de Faire U, Walldius G, Dahlén G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3.
  • 24
    Eren M, Painter CA, Atkinson JB, Declerck PJ, Vaughan DE. Age-dependent spontaneious coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation 2002; 106: 4916.
  • 25
    Schafer K, Muller K, Hecke A, Mounier E, Goebel J, Loskutoff D, Konstantinides S. Enhanced thrombosis in atherosclerosis-prone mice is associated with increased arterial expression of plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 2008; 23: 2097103.
  • 26
    Fay WP, Shapiro AD, Shih JL, Schleef RR, Ginsburg D. Complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 1992; 327: 172933.
  • 27
    Morhman SJ, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, Mahler JF, Kluckman KD, Ledford A, Lee CA, Smithies O. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995; 83: 47382.
  • 28
    Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, Czerniak PM, Gorry SA, Trzaskos JM. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995; 378: 4069.
  • 29
    Smith AA, Jacobson LJ, Miller BI, Hathaway WE, Manco-Jonson MJ. A new euglobulin clot lysis assay for global fibrinolysis. Thromb Res 2003; 112: 32937.
  • 30
    He L, Vincente CP, Westnick RJ, Eitzman DT, Tollefsen DM. Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J Clin Invest 2002; 109: 2139.
  • 31
    Dupont DM, Blouse GE, Hansen M, Mathiasen L, Kjelgaard S, Jensen JK, Christensen A, Gils A, Declerck PJ, Andreasen PA, Wind T. Evidence for a pre-latent form of the serpin plasminogen activator inhibitor-1 with detached Β-strand 1C*. J Biol Chem 2006; 281: 3607181.
  • 32
    Broze GJ, Yin ZF, Lasky N. A tail vein bleeding time model and delayed bleeding in hemophiliac mice. Thromb Haemost 2001; 85: 7478.
  • 33
    Kurien BT, Scofield R. Mouse urine collection using clear plastic wrap. Lab Anim 1999; 33: 836.
  • 34
    Davis BJ, Lennard DE, Lee CA, Tiano HF, Morham SG, Wetsel WC, Langenbach R. Anovulation in cyclooxygenase-2-deficient mice is restored by prostaglandin E2 and interleukin-1β. Endocrinology 1999; 140: 268595.
  • 35
    Loftin CD, Trivedi DB, Tiano HF, Clark JA, Lee CA, Epstein JA, Morham SG, Breyer MD, Nguyen M, Hawkins BM, Goulet JL, Smithies O, Koller BH, Langenbach R. Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2. PNAS 2001; 98: 105964.
  • 36
    Cheng Y, Wang M, Yu Y, Lawson J, Funk C, FitzGerald GA. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest 2006; 116: 13919.
  • 37
    James MJ, Walsh JA. Inter-relationships between vascular thomboxane and prostacyclin synthesis. Prostaglandins Leukot Essent Fatty Acids 1988; 31: 915.
  • 38
    Moncada S, Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, Thromboxane A2. A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2994.
  • 39
    Fernandez-Martinez MR, Bosca A, Martin-Sanz P. Prostaglandin E2 Promotes migration and adhesion in hepatocellular carcinoma cells. Carcinogenesis 2005; 26: 75361.
  • 40
    Novacek G, Kapiotis S, Jilma B, Quehenberger P, Michitsch A, Traindl O, Speiser W. Enhanced blood coagulation and enhanced fibrinolysis during hemodialysis with prostacyclin. Thromb Res 1997; 88: 28390.
  • 41
    Westrick R, Winn M, Eitzman D. Murine models of vascular thrombosis. Arterioscler Thromb Vasc Biol 2007; 27: 207993.
  • 42
    Carmeliet P, Stassen JM, Schoonjans L, Ream B, van den Oord JJ, De Mol M, Mulligan RC, Collen D. Plasminogen activator inhibitor-1 gene-deficient mice. J Clin Invest 1993; 92: 275660.